Korea Stocks, page 29 of 36 — 24 articles published 2026-07-09 ~ 2026-07-13.
A qualitative deep dive into Hana Materials (KOSDAQ 166090) for 2026: the silicon and SiC etch-consumable business model, recurring revenue tied to fab utilization, exposure to NAND and logic wafer-start growth, plus the capex-cycle, customer-concentration, and SiC-competition risks investors must weigh.
071840 (Lotte Himart) stock outlook for 2026. A qualitative deep dive into Korea's largest consumer-electronics big-box retailer: store rationalization, private-brand and refurbished push, cost cuts, and margin recovery against Coupang-led e-commerce, plus deep-value asset and dividend angles.
Mirae Company (KOSDAQ 049950) 2026 stock outlook. A qualitative deep dive into its semiconductor and display equipment cash cow (CMP planarization, edge grinding) and the high-optionality Revo-i laparoscopic surgical robot competing with Intuitive Surgical's da Vinci, plus commercialization, reimbursement, and cash-burn risks.
Shinsegae International (KOSPI 031430) 2026 stock outlook. A qualitative deep dive into its imported-luxury fashion distribution, own brands, Vidivici and Yeonjak beauty growth, China and inbound demand, plus brand-license loss and discretionary-slowdown risks.
Simmtech (222800) 2026 stock outlook: how Korea's leading semiconductor PCB and package substrate maker rides the HBM and DDR5 buildout, its FC-BGA growth push, memory capex cyclicality, Chinese competition, FX and capital-intensity risks explained qualitatively.
A qualitative 2026 stock outlook for Telechips (KOSDAQ 054450), the Korean fabless automotive SoC designer. We examine its infotainment and digital-cockpit chip business, expansion into MCUs and AI/ADAS-adjacent silicon, the rising semiconductor content-per-car theme, and the real risks around automaker adoption pace and global competition.
ABL Bio (KOSDAQ 298380) 2026 stock analysis: the Grabody-B blood-brain-barrier shuttle platform, the Sanofi Parkinson's licensing deal, 4-1BB bispecific immuno-oncology, ADC pipeline, milestone-and-royalty revenue, and the clinical and cash-burn risks.
Daejoo Electronic Materials (KOSDAQ 078600) 2026 stock analysis: silicon anode (Si anode) technology moat, conductive paste cash cow (MLCC and solar), LG Energy Solution value-chain exposure, and the EV-demand, commercialization-pace, and valuation risks investors must weigh.
Eugene Technology (KOSDAQ 084370) stock outlook for 2026. A deep, qualitative look at its LPCVD and ALD semiconductor deposition equipment moat, Samsung, SK hynix and Micron customer base, HBM and DDR5 capex leverage, plus memory-cycle volatility and customer-concentration risk.
InBody (KOSDAQ 041830) 2026 stock analysis for global investors: the world's leading body composition analyzer brand, B2B install base at hospitals and gyms, consumables and subscription recurring revenue, high overseas sales, net-cash balance sheet, and the FX, growth, and new-business risks.
Komico (KOSDAQ 183300) 2026 stock analysis: the leading semiconductor parts precision-cleaning and coating outsourcer, its fab-utilization-linked recurring revenue model, Samsung, SK hynix and Micron customer base, US, Taiwan and China expansion, AI and HBM leverage, and the memory-cycle risk.
Nano-Materials (KOSDAQ 121600) 2026 stock analysis: CNT conductive additive leverage as silicon anodes scale, the CMP slurry and TCO target businesses, EV-chasm and customer-concentration risks, valuation, and how foreign investors can access this Korean battery-materials name.
Neowiz (KOSDAQ 095660) 2026 stock analysis: how the Lies of P console hit created a global packaged-game IP, the DLC and sequel franchise path, multiplatform expansion, webboard cash cow, and the release-gap and hit-volatility risks for foreign investors.
VT Cosmetics (KOSDAQ 018290) 2026 stock analysis: Reedle Shot brand strength, explosive Japan and Amazon indie-beauty export growth, Olive Young channel, single-hit-product dependence, cosmetics trend risk, and the entertainment segment — from a global investor's view.
Webzen (069080) 2026 stock analysis for global investors: the high-margin MU (Mu Online) royalty engine, China licensing revenue, R2M, a net-cash undervalued balance sheet, and the single-IP dependence, China game-license, and cyclicality risks that cap re-rating.
Wonik QnC (KOSDAQ 074600) 2026 stock analysis: quartz-ware and cleaning consumables tied to fab utilization, HBM and etch/deposition leverage, the Momentive synthetic-quartz vertical integration, plus memory-downcycle, customer-concentration, and FX risks for global investors.
Prestige Biopharma (KOSPI 950210) 2026 stock analysis: the Tuznue trastuzumab biosimilar commercialization path and the PBP1510 (ulenistamab) pancreatic-cancer antibody's clinical and regulatory milestones, dilution risk from ongoing losses and financing, the quirks of a Singapore-domiciled foreign company listed on KOSPI, and why this is a high-risk, pipeline-driven biotech.
Kolmar BNH (KOSDAQ 200130) 2026 stock analysis: the HemoHIM proprietary ingredient, single-channel dependence on Atomy, its position inside the Korea Kolmar group as a health-functional-food ODM, export and channel diversification, and the domestic competition and channel-concentration risks that shape the investment case.
Aekyung Industrial (KOSPI: 018250) 2026 stock analysis for global investors: the AGE 20's cosmetics franchise reducing its China export dependence and rebranding, the Kerasys, 2080, and Trio household-goods cash cow, domestic consumption, raw-material and currency exposure, LINE Friends and IP collaborations, the beauty-segment rebound scenario, and Aekyung Group risk.
Cosmecca Korea (KOSDAQ: 241710) 2026 stock analysis: the cosmetics ODM/OEM manufacturing engine behind the K-beauty and indie-brand export boom, the strategic value of US subsidiary Englewood Lab and its onshore American production, the split US-China-Korea manufacturing base, customer diversification, and the input-cost, FX, and tariff variables that drive margins — analyzed qualitatively for global investors.
Grand Korea Leisure (KOSPI: 114090) 2026 stock analysis: the Seven Luck foreigner-only casino business model, Korea Tourism Organization parent (state-enterprise character), China and Japan VIP and mass tourist recovery leverage, dividend appeal, and the labor-cost, regulation, and drop-volume risks that drive earnings volatility.
Lotte Tour Development (KRX 032350) Stock Outlook 2026 covering the Jeju Dream Tower integrated resort, its foreigner-only casino drop and hold, China and Japan tourism recovery, hotel and travel operations, heavy debt and interest expense, the swing-to-profit turnaround thesis, Paradise and GKL peer comparison, and what global investors should watch.
Devsisters (194480, KOSDAQ) 2026 stock analysis for global investors: a Korean IP game maker built on the Cookie Run franchise. Cookie Run: Kingdom and OvenBreak, single-IP concentration risk, global expansion across Japan, the US and China, the new-title pipeline, hit-driven earnings volatility, and the IP-diversification thesis compared with Korean peers.
Nexon Games (KOSDAQ: 225570) 2026 stock analysis: the global Blue Archive subculture fanbase, The First Descendant console/PC push into Western markets, the Nexon parent-company umbrella, hit-driven development risk, live-service economics, game-stock valuation, and what it means for a global investor holding a Korea-listed developer.